PF415 EFFICACY AND SAFETY FOLLOWING DOSE REDUCTION OF...

HemaSphere 2019 / 06 Vol. 3; Iss. S1

PF415 EFFICACY AND SAFETY FOLLOWING DOSE REDUCTION OF BOSUTINIB IN PREVIOUSLY TREATED PATIENTS WITH CHRONIC MYELOID LEUKEMIA: ANALYSIS OF THE PHASE 4 BYOND TRIAL

Brümmendorf, T.H., Giles, F., Gambacorti-Passerini, C., Roboz, G.J., Le Coutre, P., Hjorth-Hansen, H., Stenke, L., Cervantes, F., Rousselot, P., Viqueira, A., Bardy-Bouxin, N., Leip, E., Leone, J.M.,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
3
Journal:
HemaSphere
DOI:
10.1097/01.hs9.0000559872.98250.4c
Date:
June, 2019
File:
PDF, 700 KB
2019
Conversion to is in progress
Conversion to is failed